from Reuters: Health News https://reut.rs/2EaCsVN
Sunday, December 2, 2018
Novartis SMA treatment could get FDA approval in May
Novartis's gene therapy for spinal muscular atrophy (SMA) could be approved in May 2019 after the U.S. Food and Drug Administration agreed to an accelerated review of the Swiss drugmaker's treatment.
from Reuters: Health News https://reut.rs/2EaCsVN
from Reuters: Health News https://reut.rs/2EaCsVN
Subscribe to:
Post Comments (Atom)
-
(Reuters Health) - More than half of heart failure patients who visit the emergency room don't receive prompt follow-up care, and a Cana...
-
WEIGHT LOSS supplements could help overweight or obese patients with the diet plans. You could lose weight and avoid weight gain by adding...
-
A U.S. appeals court on Wednesday declined a request by Johnson & Johnson for an temporary restraining order blocking sales of generic v...
No comments:
Post a Comment